Overview
Aplasia cutis congenita (ACC) is a rare condition characterized by the absence of skin (and sometimes underlying tissues such as subcutaneous fat, bone, or dura mater) at birth. The defect most commonly occurs on the scalp, particularly near the vertex, but can also affect the trunk, limbs, or other body areas. The lesions may appear as well-demarcated ulcers, erosions, or areas covered by a thin membrane, and they vary in size and depth. In most cases, the defect is limited to the skin and heals spontaneously with scarring and permanent alopecia in the affected area. However, deeper defects involving the skull bone or dura mater can lead to serious complications including hemorrhage, infection, or sagittal sinus thrombosis. ACC has been classified into nine groups (Frieden classification) based on the location of the defect, associated anomalies, and mode of inheritance. It can occur as an isolated finding or in association with other congenital abnormalities, including limb defects (Adams-Oliver syndrome), epidermolysis bullosa, trisomy 13 (Patau syndrome), and other genetic syndromes. Some cases are linked to fetus papyraceus (a deceased co-twin) or to in utero exposure to certain medications such as methimazole. Treatment depends on the size and depth of the defect. Small, superficial lesions are typically managed conservatively with wound care, topical antibiotics, and protective dressings, allowing healing by secondary intention. Larger or deeper defects, particularly those exposing the sagittal sinus or brain tissue, may require surgical intervention including skin grafting or flap reconstruction. Long-term outcomes are generally favorable for isolated superficial cases, though cosmetic concerns related to scarring and alopecia may require later surgical correction. Genetic counseling is recommended, especially when ACC occurs as part of a recognized syndrome.
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
1 eventUConn Health
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for Aplasia cutis congenita.
1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Rare Disease Specialist
Rare Disease Specialist
Rare Disease Specialist
Rare Disease Specialist
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Aplasia cutis congenita.
Community
No community posts yet. Be the first to share your experience with Aplasia cutis congenita.
Start the conversation →Latest news about Aplasia cutis congenita
Disease timeline:
New recruiting trial: Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
A new clinical trial is recruiting patients for Aplasia cutis congenita
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Aplasia cutis congenita
What is Aplasia cutis congenita?
Aplasia cutis congenita (ACC) is a rare condition characterized by the absence of skin (and sometimes underlying tissues such as subcutaneous fat, bone, or dura mater) at birth. The defect most commonly occurs on the scalp, particularly near the vertex, but can also affect the trunk, limbs, or other body areas. The lesions may appear as well-demarcated ulcers, erosions, or areas covered by a thin membrane, and they vary in size and depth. In most cases, the defect is limited to the skin and heals spontaneously with scarring and permanent alopecia in the affected area. However, deeper defects i
At what age does Aplasia cutis congenita typically begin?
Typical onset of Aplasia cutis congenita is neonatal. Age of onset can vary across affected individuals.
Are there clinical trials for Aplasia cutis congenita?
Yes — 1 recruiting clinical trial is currently listed for Aplasia cutis congenita on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Aplasia cutis congenita?
25 specialists and care centers treating Aplasia cutis congenita are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.